RealFeedApp Phase 3 trial showed no difference in outcomes
The pelacarsen drug successfully reduced Lp(a) levels, yet the HORIZON trial showed no reduction in heart attacks, strokes, or deaths over nearly five years.
- Field
- medicine and diagnostics
- What they did
- Researchers demonstrated that the experimental drug pelacarsen lowered Lp(a) levels but did not reduce the frequency of heart attacks, strokes, or deaths in patients over five years of observation.
- Why it matters
- This result casts doubt on current cardiovascular treatment strategies, as lowering a specific risk marker did not guarantee improved clinical outcomes.
#lipoprotein(a)#pelacarsen#cardiovascular#clinical trial#novartis
